Asymmetric dimethylarginine reference intervals determined with liquid chromatography-tandem mass spectrometry: Results from the Framingham Offspring Cohort

Clinical Chemistry

Volumn 55, Issue 8, 2009, Pages 1539-1545

  Schwedhelm, Edzard ^a   Xanthakis, Vanessa ^b   Maas, Renke ^a,c   Sullivan, Lisa M ^b,d   Schulze, Friedrich ^a   Riederer, Ulrich ^e   Benndorf, Ralf A ^a   Böger, Rainer H ^a   Vasan, Ramachandran S ^d,f  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d FRAMINGHAM HEART STUDY   (United States)

^e UNIVERSITY OF HAMBURG   (Germany)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLARGININASE; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CALCULATION; CLINICAL FEATURE; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GROUPS BY AGE; HUMAN; HYPERTENSION; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; OBESITY; PROGENY; REFERENCE VALUE; SAMPLING; SEX DIFFERENCE; TANDEM MASS SPECTROMETRY; VALIDITY;

AGE FACTORS; AGED; ARGININE; CARDIOVASCULAR DISEASES; CHROMATOGRAPHY, LIQUID; COHORT STUDIES; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; SEX FACTORS; TANDEM MASS SPECTROMETRY;

EID: 68149162181     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.124263     Document Type: Article

References (42)

1. Böger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006;38:126-136
2. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98:1842-1847.
3. Juonala M, Viikari JS, Alfthan G, Marniemi J, Kähönen M, Taittonen L, et al. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the Cardiovascular Risk in Young Finns study. Circulation 2007;116:1367-1373 (Pubitemid 47417562)
4. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 1685-1695
5. Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 2006;152: 493.e1-8 (Pubitemid 44251196)
6. Valkonen VP, PäiväH, Salonen JT, Lakka TA, Lehtimäki T, Laakso J, Laaksonen R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 200;358: 2127-2128
7. Maas R, Schulze F, Baumert J, Löwel H, Hamraz K, Schwedhelm E, et al. Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clin Chem 2007;53:693-701. (Pubitemid 46580240)
8. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005;e53-9.
9. Meinitzer A, Seelhorst U, Wellnitz B, Halwachs- Baumann G, Boehm BO, Winkelmann BR, März W. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem 2007;53:273-283 (Pubitemid 46338272)
10. Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009;119:1592-1600
11. Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Böger RH. Liquid chromatographytandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem 2005;51:1268-1271 (Pubitemid 43079411)
12. Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U, Böger RH. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007;851:211-219 (Pubitemid 46720141)
13. Dawber TR, Kannel WB, Revotskie N, Stokes J III, Kagan A, Gordon T. Some factors associated with the development of coronary heart disease: six years' follow-up experience in the Framingham study. Am J Public Health Nations Health 1959; 49:1349-1356
14. Solberg HE, Lahti A. Detection of outliers in reference distributions: performance of Horn's algorithm. Clin Chem 2005;51:2326-2332 (Pubitemid 41692577)
15. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, Levy D. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study. JAMA 2002;288: 1252-1259 (Pubitemid 35001328)
16. Kannel WB, Wolf PA, Garrison RJ, eds. The Framingham Study: an epidemiological investigation of cardiovascular disease. Section 34. Some risk factors related to the annual incidence of cardiovascular disease and death in pooled repeated biennial measurements: Framingham Heart Study, 30-year follow-up. Bethesda, MD: National Heart, Lung, and Blood Institute, February 1987 (NIH publ. no. 87-2703).
17. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, et al., Framingham Heart Study. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003;107:1486-1491
18. Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Jacques PF, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 2003; 289:1251-1257 (Pubitemid 37432905)
19. Scientific Committee, Clinical Section, Expert Panel on Theory of Reference Values (EPTRV) and International Committee for Standardization in Haematology (ICSH) Standing Committee on Reference Values. Approved recommendation (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits. Clin Chim Acta 1987;170:S13-32.
20. Fallang A, Larsen S, Horsberg TE. Upper susceptibility threshold limits with confidence intervals: a method to identify normal and abnormal population values for laboratory toxicological parameters, based on acetylcholinesterase activities in sea lice. Pest Manag Sci 2006;62:208-213
21. Horn PS, Pesce AJ, Copeland BE. A robust approach to reference interval estimation and evaluation. Clin Chem 1998;44:622-631 (Pubitemid 28141361)
22. Teerlink T. HPLC analysis of ADMA and other methylated L-arginine analogs in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci 2007;851:21-29 (Pubitemid 46720132)
23. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, Wang BY, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 2003;108:3042-3047 (Pubitemid 37553576)
24. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O'Hara B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007;13:198-203. (Pubitemid 46245768)
25. Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 2007;293:H3227-45. (Pubitemid 350230862)
26. Meinitzer A, Puchinger M, Winklhofer-Roob BM, Rock E, Ribalta J, Roob JM, et al. Reference values for plasma concentrations of asymmetrical dimethylarginine (ADMA) and other arginine metabolites in men after validation of a chromatographic method. Clin Chim Acta 2007;384: 141-148 (Pubitemid 47248653)
27. Schulze F, Maas R, Freese R, Schwedhelm E, Silberhorn E, Böger RH. Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest 2005;35:622-626 (Pubitemid 41406726)
28. Hov GG, Sagen E, Bigonah A, Asberg A. Healthassociated reference values for arginine, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) measured with highperformance liquid chromatography. Scand J Clin Lab Invest 2007;67:868-876 (Pubitemid 350158772)
29. Teerlink T, Neele SJ, de Jong S, Netelenbos JC, Stehouwer CD. Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clin Sci (Lond) 2003;105:67-71. (Pubitemid 36819578)
30. Post MS, Verhoeven MO, van der Mooren MJ, Kenemans P, Stehouwer CD, Teerlink T. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebocontrolled 12-week study in healthy early postmenopausal women. J Clin Endocrinol Metab 2003;88:4221-4226 (Pubitemid 37153723)
31. Holden DP, Cartwright JE, Nussey SS, Whitley GS. Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine. Circulation. 2003; 108:1575-1580
32. Wang J, Sim AS, Wang XL, Salonikas C, Naidoo D, Wilcken DE. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis 2006;184:383-388
33. Stühlinger MC, Oka RK, Graf EE, Schmölzer I, Upson BM, Kapoor O, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 2003; 108:933-938 (Pubitemid 37048221)
34. Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2002;104:2569-2575 (Pubitemid 33104795)
35. Schmitt B, Wolters M, Kressel G, Hülsmann O, Ströhle A, Kühn-Velten WN, et al. Effects of combined supplementation with B vitamins and antioxidants on plasma levels of asymmetric dimethylarginine (ADMA) in subjects with elevated risk for cardiovascular disease. Atherosclerosis 2007;193:168-176 (Pubitemid 46779119)
36. Kelemen LE, Anand SS, Hegele RA, Stampfer MJ, Rosner B, Willett WC, et al. Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians. Atherosclerosis 2004;176:361-370 (Pubitemid 39369527)
37. Furuki K, Adachi H, Matsuoka H, Enomoto M, Satoh A, Hino A, et al. Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: an epidemiological study. Atherosclerosis 2007;191: 206-210 (Pubitemid 46227419)
38. Nanayakkara PW, Teerlink T, Stehouwer CD, Allajar D, Spijkerman A, Schalkwijk C, et al. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int 2005;68:2230-2236 (Pubitemid 43117798)
39. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-2117 (Pubitemid 34094901)
40. Kielstein JT, Böger RH, Bode-Böger SM, Frölich JC, Haller H, Ritz E, Fliser D. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002;13:170-176 (Pubitemid 34042024)
41. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005; 46:518-523 (Pubitemid 41040296)
42. Valkonen VP, Tuomainen TP, Laaksonen R. DDAH gene and cardiovascular risk. Vasc Med 2005;10 Suppl 1:S45-8. (Pubitemid 43137267)